Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Calcium salt

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Calcium salt. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-000035-82 Sponsor Protocol Number: 027-008 Start Date*: 2012-10-22
    Sponsor Name:Biogen GmbH
    Full Title: A 2:1 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Fumaderm® in young patients aged 10 to 17 years with moderate to severe psoriasis vulgaris (KIFUder...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000924-11 Sponsor Protocol Number: CTCL Start Date*: 2015-06-17
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor
    Full Title: Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.
    Medical condition: Cutaneous T cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000055-13 Sponsor Protocol Number: M41008-1102 Start Date*: 2012-12-10
    Sponsor Name:Almirall S.A.
    Full Title: A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moder...
    Medical condition: moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10071117 Plaque psoriasis LLT
    17.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004155-67 Sponsor Protocol Number: PRIMUS0012016 Start Date*: 2017-08-01
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: PRIMUS 001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker e...
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004156-29 Sponsor Protocol Number: PRIMUS0022016 Start Date*: 2018-08-13
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: PRIMUS 002: An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal Carcinoma (PDAC), focusing on biomarker and l...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033608 Pancreatic cancer resectable LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003660-13 Sponsor Protocol Number: E-DIS-2-1705 Start Date*: 2018-02-21
    Sponsor Name:Centre Oscar Lambret
    Full Title: Phase II Randomized Study Measuring the Interest of Pursuing or Not the chemotherapy for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel ...
    Medical condition: Patients suffering from squamous-cell type esophageal cancer histologically proved and with metastatic disease measurable according to RECIST criteria. Patients with metachronous metastasis and w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005215-29 Sponsor Protocol Number: 03-CoFactor Start Date*: 2005-06-03
    Sponsor Name:ADVENTRX Pharmaceuticals Inc
    Full Title: A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU versus Leucovorin and 5-FU in Subjects with Metastatic Colo...
    Medical condition: Metastatic Colorectal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10052358 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005685-35 Sponsor Protocol Number: FP187-301 Start Date*: 2013-10-11
    Sponsor Name:Forward Pharma GmbH
    Full Title: A randomised, double blind, double dummy, active comparator and placebo controlled confirmative non-inferiority trial of FP187 compared to Fumaderm in moderate to severe plaque psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001471-36 Sponsor Protocol Number: PrimeRT-2018 Start Date*: 2020-10-05
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. The University of Glasgow
    Full Title: Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer: A Phase II trial of Durvulamab in Combination with Extended Neoadjuvant Regimens i...
    Medical condition: Rectal Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-015217-52 Sponsor Protocol Number: Uni-Koeln-1251 Start Date*: 2010-06-08
    Sponsor Name:University of Cologne
    Full Title: Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate
    Medical condition: In this study we will prospectively analyze the reduction of urinary oxalate excretion under the treatment with PLP in dosages of 5mg/kg/day up to 20 mg/kg/day and serum level response relationship...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037671 Pyridoxine deficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004418-16 Sponsor Protocol Number: B24CS Start Date*: Information not available in EudraCT
    Sponsor Name:Advicenne SA
    Full Title: A Phase 3b Open-Label Extension of Study B23CS (ARENA 2) Evaluating the Continued Safety and Efficacy of ADV7103 in Subjects With Primary Distal Renal Tubular Acidosis (ARENA 2 Open-label Extensio...
    Medical condition: Distal renal tubular acidosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10038535 Renal tubular acidosis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013228-21 Sponsor Protocol Number: Start Date*: 2010-07-06
    Sponsor Name:University of Oxford
    Full Title: Prevention of atrial oxidative stress and electrical remodelling in patients undergoing cardiac surgery: randomised placebo-controlled trial of perioperative high-dose atorvastatin
    Medical condition: POST-OPERATIVE ATRIAL FIBRILLATION
    Disease: Version SOC Term Classification Code Term Level
    13 10003658 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004447-80 Sponsor Protocol Number: SFN-2-2019 Start Date*: 2021-05-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with type 2 diabetes and chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Type 2 diabetes with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    23.1 100000004857 10076408 Chronic kidney disease stage 1 LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    23.1 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000526-23 Sponsor Protocol Number: A6181049 Start Date*: 2005-08-30
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Medical condition: Metastatic colorectal cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004467-50 Sponsor Protocol Number: SFN-3-2019 Start Date*: 2021-05-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with non-diabetic chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076408 Chronic kidney disease stage 1 LLT
    23.1 100000004857 10076409 Chronic kidney disease stage 2 LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001149-14 Sponsor Protocol Number: A6181034 Start Date*: 2004-09-27
    Sponsor Name:PFIZER
    Full Title: A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma.
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050513 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000659-18 Sponsor Protocol Number: FumadermAA01 Start Date*: 2011-08-22
    Sponsor Name:University Hospital Tübingen
    Full Title: Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001270-27 Sponsor Protocol Number: A6181061 Start Date*: 2005-08-17
    Sponsor Name:PFIZER LTD
    Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CARCINOMA
    Medical condition: Histologically confirmed renal cell carcinoma with metastases with a component of clear (conventional) cell histology
    Disease: Version SOC Term Classification Code Term Level
    7,1 10038415
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001713-14 Sponsor Protocol Number: PROCEED Start Date*: 2011-05-18
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE ANTIPROTEINURIC EFFECT OF SELECTIVE VITAMIN D RECEPTOR ACTIVATION BY PARICALCITOL IN TYPE 2 DIABETES PATI...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000476-33 Sponsor Protocol Number: GC-SU-2006 Start Date*: 2006-11-20
    Sponsor Name:Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik
    Full Title: An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer
    Medical condition: Chemorefractory metastatic adenocarcinoma of stomach, esophagogastric junction and lower esophagus (Barrett carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 16:06:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA